সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
lenalidomid aristo 7,5 mg kapsel, hård
aristo pharma gmbh - lenalidomid - kapsel, hård - 7,5 mg - lenalidomid 7,5 mg aktiv substans; laktos (vattenfri) hjälpämne; para-orange hjälpämne; propylenglykol hjälpämne
ইউরোপীয় ইউনিয়ন -
সুইডিশ -
EMA (European Medicines Agency)
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrelbesilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiska medel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentet höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. för ytterligare information hänvisas till avsnitt 5.
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
fingolimod aristo 0,5 mg kapsel, hård
aristo pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - natriumlaurilsulfat hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
bosentan aristo 62,5 mg filmdragerad tablett
aristo pharma gmbh - bosentanmonohydrat - filmdragerad tablett - 62,5 mg - bosentanmonohydrat 64,541 mg aktiv substans
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
bosentan aristo 125 mg filmdragerad tablett
aristo pharma gmbh - bosentanmonohydrat - filmdragerad tablett - 125 mg - bosentanmonohydrat 129,082 mg aktiv substans
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
acetylcystein viatris 200 mg brustablett
viatris limited - acetylcystein - brustablett - 200 mg - sorbitol hjälpämne; mannitol hjälpämne; laktos (vattenfri) hjälpämne; acetylcystein 200 mg aktiv substans - acetylcystein
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
atenolol viatris 25 mg tablett
viatris limited - atenolol - tablett - 25 mg - atenolol 25 mg aktiv substans - atenolol
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
atenolol viatris 50 mg tablett
viatris limited - atenolol - tablett - 50 mg - atenolol 50 mg aktiv substans - atenolol
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
atorvastatin viatris 10 mg filmdragerad tablett
viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 10,844 mg aktiv substans - atorvastatin
সুইডেন -
সুইডিশ -
Läkemedelsverket (Medical Products Agency)
atorvastatin viatris 20 mg filmdragerad tablett
viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 21,688 mg aktiv substans - atorvastatin